113 related articles for article (PubMed ID: 19248289)
1. Antigenic and genetic characteristics of H5N1 viruses and candidate vaccine viruses developed for potential use in human vaccines, February 2009.
Wkly Epidemiol Rec; 2009 Feb; 84(9):72-6. PubMed ID: 19248289
[No Abstract] [Full Text] [Related]
2. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines, March 2007.
Wkly Epidemiol Rec; 2007 May; 82(19):164-7. PubMed ID: 17500103
[No Abstract] [Full Text] [Related]
3. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010.
Wkly Epidemiol Rec; 2010 Mar; 85(11):100-7. PubMed ID: 20229648
[No Abstract] [Full Text] [Related]
4. Antigenic and genetic characteristics of influenza A(H5N1) viruses and candidate vaccine viruses developed for potential use in human vaccines.
Wkly Epidemiol Rec; 2009 Oct; 84(41):432-6. PubMed ID: 19817020
[No Abstract] [Full Text] [Related]
5. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness - February 2011.
Wkly Epidemiol Rec; 2011 Mar; 86(11):93-100. PubMed ID: 21395189
[No Abstract] [Full Text] [Related]
6. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines.
Wkly Epidemiol Rec; 2006 Aug; 81(34/35):328-30. PubMed ID: 16933379
[No Abstract] [Full Text] [Related]
7. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
Wkly Epidemiol Rec; 2011 Oct; 86(43):469-80. PubMed ID: 22046595
[No Abstract] [Full Text] [Related]
8. Antigenic and genetic characteristics of influenza A(H5N1)and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines.
Wkly Epidemiol Rec; 2010 Oct; 85(42):418-24. PubMed ID: 20949701
[No Abstract] [Full Text] [Related]
9. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
Wkly Epidemiol Rec; 2014 Oct; 89(42):457-64. PubMed ID: 25337626
[No Abstract] [Full Text] [Related]
10. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
[TBL] [Abstract][Full Text] [Related]
11. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for pandemic influenza.
Luke CJ; Subbarao K
Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
[TBL] [Abstract][Full Text] [Related]
14. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
Wkly Epidemiol Rec; 2015 Mar; 90(12):109-20. PubMed ID: 25796641
[No Abstract] [Full Text] [Related]
15. Recommended composition of influenza virus vaccines for use in the 2008 influenza season.
Wkly Epidemiol Rec; 2007 Oct; 82(40):351-6. PubMed ID: 17918656
[No Abstract] [Full Text] [Related]
16. [Engineering by reverse genetics and characterization of the new reassortant influenza virus strain H5N1].
Zeberezhnyĭ AD; Grebennikova TV; Vorkunova GK; Yuzhakov AG; Kostina LV; Norkina SN; Aliper TI; Nepoklonov EA; Lvov DK
Vopr Virusol; 2014; 59(6):23-7. PubMed ID: 25929032
[TBL] [Abstract][Full Text] [Related]
17. How can we develop universal H5N1 vaccines.
Tan Y; He F; Kwang J
Immunotherapy; 2015; 7(7):713-6. PubMed ID: 26250411
[TBL] [Abstract][Full Text] [Related]
18. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
[TBL] [Abstract][Full Text] [Related]
19. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
20. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
